Efficacy and Safety of Oral Ritlecitinib for the Treatment of Active Nonsegmental Vitiligo: A Randomized Phase 2b Clinical Trial.
Journal of the American Academy of Dermatology(2022)
Abstract
Oral ritlecitinib was effective and well-tolerated over 48 weeks in patients with active NSV.
MoreTranslated text
Key words
JAK inhibitor,JAK/STAT signaling,TEC inhibitor,VASI,Vitiligo,randomized clinical trial,ritlecitinib,skin depigmentation
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined